Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1889 1
1892 1
1895 1
1896 1
1902 1
1905 4
1906 1
1907 1
1908 1
1909 2
1910 3
1911 5
1913 5
1914 1
1915 1
1916 1
1917 4
1918 2
1919 2
1921 2
1925 1
1926 1
1929 3
1931 2
1934 2
1935 1
1940 1
1944 1
1945 3
1946 7
1947 9
1948 15
1949 17
1950 13
1951 24
1952 36
1953 57
1954 43
1955 50
1956 25
1957 44
1958 40
1959 37
1960 24
1961 36
1962 33
1963 90
1964 111
1965 98
1966 101
1967 101
1968 125
1969 143
1970 129
1971 135
1972 136
1973 148
1974 158
1975 133
1976 124
1977 127
1978 109
1979 128
1980 106
1981 134
1982 160
1983 158
1984 171
1985 227
1986 265
1987 245
1988 298
1989 295
1990 310
1991 291
1992 304
1993 312
1994 284
1995 312
1996 255
1997 242
1998 198
1999 202
2000 203
2001 200
2002 206
2003 189
2004 209
2005 242
2006 275
2007 288
2008 274
2009 301
2010 310
2011 326
2012 329
2013 345
2014 349
2015 286
2016 266
2017 314
2018 312
2019 306
2020 304
2021 236
Text availability
Article attribute
Article type
Publication date

Search Results

12,782 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
Renner UD, Oertel R, Kirch W. Renner UD, et al. Ther Drug Monit. 2005 Oct;27(5):655-65. doi: 10.1097/01.ftd.0000168293.48226.57. Ther Drug Monit. 2005. PMID: 16175141 Review.
The alkaloid L-(-)-scopolamine [L-(-)-hyoscine] competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects …
The alkaloid L-(-)-scopolamine [L-(-)-hyoscine] competitively inhibits muscarinic receptors for acetylcholine and acts as a no …
Scopolamine (hyoscine) for preventing and treating motion sickness.
Spinks A, Wasiak J. Spinks A, et al. Cochrane Database Syst Rev. 2011 Jun 15;2011(6):CD002851. doi: 10.1002/14651858.CD002851.pub4. Cochrane Database Syst Rev. 2011. PMID: 21678338 Free PMC article. Review.
Scopolamine was compared against placebo, calcium channel antagonists, antihistamine, methscopolamine or a combination of scopolamine and ephedrine. ...Evidence comparing scopolamine to cinnarizine or combinations of scopolamine and ephedrine is equivo
Scopolamine was compared against placebo, calcium channel antagonists, antihistamine, methscopolamine or a combination of scopolam
Scopolamine?
Selman D. Selman D. J Am Coll Cardiol. 2002 Feb 20;39(4):744-5. J Am Coll Cardiol. 2002. PMID: 11849885 Free article. No abstract available.
Scopolamine in racing horses: trace identifications associated with dietary or environmental exposure.
Brewer K, Dirikolu L, Hughes CG, Tobin T. Brewer K, et al. Vet J. 2014 Mar;199(3):324-31. doi: 10.1016/j.tvjl.2013.12.013. Epub 2013 Dec 14. Vet J. 2014. PMID: 24440440 Review.
Scopolamine (L-hyoscine) identifications, often in small-number clusters, have been reported worldwide in performance horses over the last 30 years. ...As such, scopolamine identification(s) in race or performance horses can result in significant penal
Scopolamine (L-hyoscine) identifications, often in small-number clusters, have been reported worldwide in performance horses o
The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions.
Drevets WC, Bhattacharya A, Furey ML. Drevets WC, et al. Adv Pharmacol. 2020;89:357-386. doi: 10.1016/bs.apha.2020.04.002. Epub 2020 Jun 18. Adv Pharmacol. 2020. PMID: 32616213 Review.
Scopolamine is a nonselective muscarinic antagonist that has shown relatively rapid antidepressant effects, although to date the results are from limited clinical studies. ...The preclinical data associated with scopolamine also are reviewed and convey a vision for
Scopolamine is a nonselective muscarinic antagonist that has shown relatively rapid antidepressant effects, although to date the resu
[Scopolamine-Scopolia-Scopoli].
WANNENMACHER R. WANNENMACHER R. Med Monatsschr. 1960 Sep;14:601-3. Med Monatsschr. 1960. PMID: 13783074 German. No abstract available.
Long-term scopolamine treatment and dental caries.
Galili E, Averbuch Zehavi E, Zadik Y, Caspi T, Meltzer L, Merdler I, Kuten J, Tal D. Galili E, et al. Clin Oral Investig. 2019 May;23(5):2339-2344. doi: 10.1007/s00784-018-2688-3. Epub 2018 Oct 8. Clin Oral Investig. 2019. PMID: 30298452
OBJECTIVES: To investigate whether scopolamine, an anticholinergic agent which induces hyposalivation, represents a risk factor for the occurrence of dental caries. ...CONCLUSIONS: In healthy young adults, prolonged intermittent use of scopolamine was found to be a …
OBJECTIVES: To investigate whether scopolamine, an anticholinergic agent which induces hyposalivation, represents a risk factor for t …
Tropane alkaloids.
Fodor G, Dharanipragada R. Fodor G, et al. Nat Prod Rep. 1988 Feb;5(1):67-72. doi: 10.1039/np9880500067. Nat Prod Rep. 1988. PMID: 3045701 Review. No abstract available.
Scopolamine (hyoscine) for preventing and treating motion sickness.
Spinks AB, Wasiak J, Villanueva EV, Bernath V. Spinks AB, et al. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD002851. doi: 10.1002/14651858.CD002851.pub3. Cochrane Database Syst Rev. 2007. PMID: 17636710 Free article. Updated. Review.
Scopolamine was compared against placebo, calcium channel antagonists, antihistamine, methscopolamine or a combination of scopolamine and ephedrine. ...Evidence comparing scopolamine to cinnarizine or combinations of scopolamine and ephedrine is equivo
Scopolamine was compared against placebo, calcium channel antagonists, antihistamine, methscopolamine or a combination of scopolam
12,782 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page